PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111)

Abstract

Category: 18. Indolent and mantle-cell non-Hodgkin lymphoma-Clinical Keywords (0-4 required): Waldenström macroglobulinemia Has this abstract been presented or submitted elsewhere? No Presentation Preference (can only select oral, poster, or publication only: Oral Current character count: 3399/3600 Background: Zanubrutinib, an investigational BTK inhibitor, achieves high plasma concentrations and sustained complete BTK occupancy in blood and lymph nodes, with greater selectivity for BTK vs other TEC-and EGFR-family kinases in biochemical assays, and favorable pharmacokinetic/pharmacodynamic properties in preclinical studies.